Delcath Systems Inc
DCTH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$487.17M
Close$
$1.07
92.5% downside
Current Fair Value
92.5% downsideOvervalued by 92.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $487.17 Million |
|---|---|
| Enterprise Value | $442.11 Million |
| Earnings per Share | $0.08 |
| Beta | 0.6 |
| Outstanding Shares | 35,891,915 |
Return
| Return on Equity | 0.44% |
|---|---|
| Return on Assets | 0.39% |
| Return on Invested Capital | 0.45% |
Valuation & Multiples
| P/E Ratio | 1276.36 |
|---|---|
| PEG | -118701.82 |
| Price to Sales | 14.29 |
| Price to Book Ratio | 4.76 |
| Enterprise Value to Revenue | 8.9 |
| Enterprise Value to EBIT | 785.28 |
| Enterprise Value to Net Income | 831 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.09
Consensus analyst estimateRevenue Estimate
$26.25 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.10
Consensus analyst estimateRevenue Estimate
$26.00 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 58.06% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.37%▼ 47.23% |
|---|---|
| Total Invested | $7.84M▼ 96.44% |
| Investors Holding | 28▼ 101.00% |
About Delcath Systems Inc
CEO: Jennifer Simpson
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...